Company
Insulet
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
19
510(k), De Novo and PMA
Device trials
23
As lead sponsor, any status
Adverse event reports
92,464
Received Nov 1, 2025 to Nov 20, 2026
Recall records
21
One per recalled product
Insulet is on our public-company list (ticker PODD). Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements.
Listed
PODD
Nasdaq · INSULET CORP
Public float
$22.1B
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$2.71B
Fiscal year ending Dec 31, 2025
Net income
$247M
Fiscal year ending Dec 31, 2025
R&D spending
$301M
Fiscal year ending Dec 31, 2025
Cash
$584M
As of Sep 30, 2026
Long-term debt
$943M
As of Sep 30, 2026
Shares outstanding
69.4M
As of Oct 27, 2026
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
The 8 newest of 19 since 2015.
- Omnipod 6 algorithm510(k)
K261461 · Decided Jun 29, 2026 · 56 days after receipt
Device type: Interoperable Automated Glycemic Controller (QJI) · Laboratory Medicine & Pathology
- Omnipod 5 algorithm510(k)
K251779 · Decided Dec 3, 2025 · 176 days after receipt
Device type: Interoperable Automated Glycemic Controller (QJI) · Laboratory Medicine & Pathology
- SmartAdjust Technology510(k)
K241777 · Decided Aug 26, 2024 · 67 days after receipt
Device type: Interoperable Automated Glycemic Controller (QJI) · Laboratory Medicine & Pathology
16 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and AdultsPivotal-lookingCompleted
NCT05923827 · 189 participants · Start Sep 11, 2023 · Primary completion Aug 16, 2024
Device: Omnipod 5 System · For: Diabetes Mellitus, Type 1
Sites: Brussels, Belgium; Leuven, Belgium; Caen, France · 19 sites in all
NCT07593625 · 80 participants (planned) · Start May 25, 2026 · Primary completion Dec 31, 2026
Device: Omnipod M System; Omnipod S · For: Type 1 Diabetes; Type 1 Diabetes Mellitus; Diabetes (DM)
Sites: Christchurch, New Zealand
NCT07317102 · 152 participants (planned) · Start Mar 16, 2026 · Primary completion Nov 2027
Device: Omnipod 5 · For: Diabetes; Type 1 Diabetes; Diabetes Mellitus
Sites: Angers, France; Besançon, France; Bobigny, France · 24 sites in all
20 more trials with a free account
Reports received
92,464
Received Nov 1, 2025 to Nov 20, 2026. Includes 92 of another or unstated type.
Malfunction reports
82,010
89% of reports
Injury reports
10,234
11% of reports
Death reports
128
0.1% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 2,992 | 337 | 2 | 0 |
| Jan 24 | 3,180 | 429 | 3 | 0 |
| Feb 24 | 3,528 | 418 | 3 | 0 |
| Mar 24 | 3,443 | 336 | 1 | 0 |
| Apr 24 | 3,958 | 393 | 1 | 0 |
| May 24 | 4,113 | 426 | 0 | 1 |
| Jun 24 | 3,674 | 333 | 0 | 1 |
| Jul 24 | 4,970 | 391 | 2 | 1 |
| Aug 24 | 4,754 | 430 | 2 | 0 |
| Sep 24 | 4,510 | 329 | 0 | 1 |
| Oct 24 | 4,492 | 431 | 1 | 0 |
| Nov 24 | 3,545 | 389 | 3 | 0 |
| Dec 24 | 3,269 | 374 | 1 | 0 |
| Jan 25 | 4,214 | 447 | 3 | 0 |
| Feb 25 | 3,642 | 361 | 1 | 0 |
| Mar 25 | 4,757 | 498 | 2 | 0 |
| Apr 25 | 4,490 | 503 | 1 | 1 |
| May 25 | 4,208 | 430 | 3 | 0 |
| Jun 25 | 4,993 | 514 | 3 | 0 |
| Jul 25 | 4,879 | 481 | 0 | 0 |
| Aug 25 | 4,116 | 435 | 1 | 0 |
| Sep 25 | 5,785 | 528 | 3 | 0 |
| Oct 25 | 7,238 | 581 | 2 | 0 |
| Nov 25 | 5,983 | 494 | 7 | 0 |
| Dec 25 | 5,159 | 595 | 4 | 0 |
| Jan 26 | 4,354 | 477 | 3 | 0 |
| Feb 26 | 5,593 | 534 | 3 | 0 |
| Mar 26 | 5,732 | 631 | 7 | 0 |
| Apr 26 | 6,600 | 960 | 14 | 0 |
| May 26 | 6,132 | 935 | 12 | 0 |
| Jun 26 | 7,959 | 1,185 | 12 | 0 |
| Jul 26 | 9,830 | 1,346 | 30 | 30 |
| Aug 26 | 9,330 | 1,173 | 19 | 21 |
| Sep 26 | 8,943 | 1,047 | 13 | 20 |
| Oct 26 | 6,395 | 857 | 4 | 21 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
2 more in this ranking with a free account
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
- OMNIPOD 5 PODS36,434
- OMNIPOD 5 POD14,245
7 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2603-2026 · Started May 20, 2026 · Posted by FDA Jun 30, 2026
Reason given: External soft cannula damage during manufacturing that results in insulin leaking around the Pod instead of being delivered to the user regardless of basal or bolus delivery. The primary failure mode is pump under-delivery due to loss of insulin to an external leak. If insulin is not delivered properly, users may...
Cause as FDA categorized it: Process design · Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG)
Z-2604-2026 · Started May 20, 2026 · Posted by FDA Jun 30, 2026
Reason given: External soft cannula damage during manufacturing that results in insulin leaking around the Pod instead of being delivered to the user regardless of basal or bolus delivery. The primary failure mode is pump under-delivery due to loss of insulin to an external leak. If insulin is not delivered properly, users may...
Cause as FDA categorized it: Process design · Device type: Pump, Infusion, Insulin (LZG)
Z-2605-2026 · Started May 20, 2026 · Posted by FDA Jun 30, 2026
Reason given: External soft cannula damage during manufacturing that results in insulin leaking around the Pod instead of being delivered to the user regardless of basal or bolus delivery. The primary failure mode is pump under-delivery due to loss of insulin to an external leak. If insulin is not delivered properly, users may...
Cause as FDA categorized it: Process design · Device type: Pump, Infusion, Insulin (LZG)
18 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.